A large trial of dexamethasone has shown the low-cost steroid can cut deaths in patients hospitalized with severe COVID-19 by up to a third, making it the first drug to show any lifesaving benefits for these patients.
The data are in contrast with disappointing results from multiple trials of repurposed antimalarial hydroxychloroquine, and even Gilead Sciences Inc.’s remdesivir, which has only shown limited benefits in shortening...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?